project id: TCGA-PRAD; case submitter id: TCGA-VN-A88R; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.93; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.67; rna integrity number: 8.8; age at index: 53; days to birth: -19513; ethnicity: not hispanic or latino; gender: male; race: black or african american; vital status: Alive; year of birth: 1959; age at diagnosis: 19513; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 784.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 402; initial weight: 40.0; sample id: 8ce015a1-c0c7-4e58-a8f8-9e9650b22789; sample submitter id: TCGA-VN-A88R-01A; portion id: de26c989-491e-4526-9c57-6d03989dccc3; portion submitter id: TCGA-VN-A88R-01A-11; slide id: 2f090513-e822-4724-bb5f-22179936cf56; slide submitter id: TCGA-VN-A88R-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 70.0; percent tumor nuclei: 85.0; section location: TOP;